Home » Biotech Stocks May Have Finally Been Unleashed

Biotech's Stock May Have Finally Been Unleashed

Biotech Stocks May Have Finally Been Unleashed

Biotech Stocks May Have Finally Been Unleashed

Michael Kramer and the Clients of Mott Capital Own CELG

Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month

Join this channel to get access to perks:https://www.youtube.com/channel/UCIIr1ooRsSukPL7rKNr0VHQ/joinPlease check out my content on Substack and Seeking Alpha:https://www.themarketchronicle.com/https://seekingalpha.com/affiliate_link/Youtube81624#sp500 #stocks #stockmarket #cpi #fed #qqq #spy #rates Charts used with the permission of Bloomberg Finance L.P. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment. 7:28
YouTube Video VVVNT0lJcjFvb1JzU3VrUEw3cktOcjBWSFEublBaS280VmljSkE

What A Bear Steepener Could Mean For The Market

13 hours ago

Join this channel to get access to perks:https://www.youtube.com/channel/UCIIr1ooRsSukPL7rKNr0VHQ/joinPlease check out my content on Substack and Seeking Alpha:https://www.themarketchronicle.com/https://seekingalpha.com/affiliate_link/Youtube81624#sp500 #stocks #stockmarket #cpi #fed #qqq #spy #rates Charts used with the permission of Bloomberg Finance L.P. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment. 36:38
YouTube Video VVVNT0lJcjFvb1JzU3VrUEw3cktOcjBWSFEuY293OTdCLWUwZXM

CPI Day Live Replay 9.10.24

October 10, 2024 8:57 AM

Join this channel to get access to perks:https://www.youtube.com/channel/UCIIr1ooRsSukPL7rKNr0VHQ/joinPlease check out my content on Substack and Seeking Alpha:https://www.themarketchronicle.com/https://seekingalpha.com/affiliate_link/Youtube81624#sp500 #stocks #stockmarket #cpi #fed #qqq #spy #rates Charts used with the permission of Bloomberg Finance L.P. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment. 13:30
YouTube Video VVVNT0lJcjFvb1JzU3VrUEw3cktOcjBWSFEuUFl1WkRaQ1k2Wnc

CPI Preview and Potential Impacts

October 9, 2024 2:06 PM

Load More... Subscribe

[widget id=”text-19″]

Stocks continued to move higher, led by the Biotech’s, which were up by about 3 percent. There’s something we haven’t said in a long time. The highly anticipated speech regarding drug prices by the President didn’t seem to be as bad as many had feared. Increasing competition, deregulation, cutting out the middlemen, is at the core of the proposals, based on my interpretation.

The drug pricing overhang had plagued this sector since September 2015, when Hillary Clinton made it a political point in the race for President. If this is the worst of it, I think the group might have much further to rise. Companies like Celgene, Gilead, Biogen, and Amgen are all trading at some of their lowest earnings multiples in years. Albeit for good reasons in some cases, but some of the valuations seem excessively low.

The details aren’t fully known yet, and what ends up getting put into law may be very different. But just knowing the blueprint for how they plan to tackle drug pricing might unleash the sector from the shackles of the past three years.

I think the group is likely heading higher.
biotech

[widget id=”text-22″]

S&P 500

The S&P 500 continues to rally, and finished near the highs at 2727, up about 2.5 percent. The setup continues to look strong.

sp500

[widget id=”text-16″]

Amazon

Technology stocks continue to look strong as well and so do consumer stocks, even though Amazon still didn’t break out.  $1620 is proving, for now, to be tough for Amazon. Now that I’m calling for it to rise, it will probably go down! Ugh. We shall see.

amazon

[widget id=”wordads_sidebar_widget-41″]

Nvidia

I’m surprised Nvidia was down today. But I also do not think today’s price actions mean the stock is going lower. Shares held firmly above support around $253. The results were stunning, and this probably keeps working higher.

nvda

[widget id=”text-28″]

Amgen

Amgen shares continue to look strong as well, with a well-defined double bottom, and what looks like a solid path towards $178 to $180 range.

amgen

[widget id=”wordads_sidebar_widget-41″]

Gilead

Gilead also looks as if it could see a rise to about $72.

gilead

[widget id=”text-22″]

Biogen

Biogen also looks like it is on the cusp of a big breakout.

biogen

That is going to be it for today.

Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

The Setup In Stocks Continues To Improve

Getting Long Apple

A Rise Back To 2,800 On The S&P Is In The Works

Why It Is Time To Dump Starbucks, Plus A Look At ACAD

The Market Continues To Sink

It’s Back! Apple Investors Are Worried Once Again

A Review Of Netflix, IBM And Earnings Outlook

Free Articles Written By Mike:

Broadcom Traders Bet on 12% Rebound

Costco May Plunge 11% as Growth Slows

Square’s Stock Seen Rising 12% By June

Disney’s Stock Is Poised to Rise By 10%

Gilead May Rebound By 12% Short Term

Tesla Stock May Break Out, Fueling a 10% Increase

Alphabet’s Battered Stock May Jump 7% Short Term

3 Overvalued Stocks That May Fall Sharply

3 Tech Stocks Nearing a Breakout

Roku’s Stock Faces Huge 17% Price Swing on Results

Nvidia’s Stock Poised For Big 8% Jump On Earnings

Amazon Traders Bet Stock Will Rise 12% Further

Microsoft Bulls Look for More Big Gains

Why S&P 500 Stocks May Rebound 6% Short Term

Chipmakers May Soon Rebound to New Highs

Biotech Stocks Set to Breakout

Join our 2,662 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

Photo credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #biotech #amgen #gilead #biogen #technology #amazon #sp500

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!